Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction

BACKGROUND: Trastuzumab is life‐extending therapy for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2+), but has known cardiotoxic risk. We sought to determine if trastuzumab can be administered to patients with reduced baseline cardiac function at no higher...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Am Heart Assoc
Prif Awduron: Nowsheen, Somaira, Aziz, Khaled, Park, Jae Yoon, Lerman, Amir, Villarraga, Hector R., Ruddy, Kathryn Jean, Herrmann, Joerg
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201446/
https://ncbi.nlm.nih.gov/pubmed/30371238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.008637
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg